Author: Sumner J. Yaffe Publisher: Lippincott Williams & Wilkins ISBN: 0781795389 Category : Medical Languages : en Pages : 1072
Book Description
"Neonatal and Pediatric Pharmacology offers guidelines for safe, effective, and rational drug therapy in newborns, children and adolescents. The book provides relevant and useful data on the molecular, physiologic, biochemical, and pharmacologic mechanisms of drug action and therapy in this population. The authors identify areas of innovative basic and translational research necessary for the continuing evaluation and development of drugs for the fetus, newborns, children and adolescents. Neonatal and Pediatric Pharmacology is is a valuable reference for all health care professionals who treat the fetus, newborns, children, and adolescents, including neonatologists, nurses, pediatricians, general practitioners, students, obstetricians, perinatologists, surgeons and allied health professionals. It will be useful anytime during the day and especially in the middle of the night when knowledge of appropriate indications, safe and effective use, dosage, and therapeutic regimen for a certain drug or molecular entity is immediately needed. The book is also directed to those involved in basic, clinical, and other academic pharmacological research, the pharmaceutical industry, and regulatory agencies dealing with drug and therapeutic developments for this population. Those teaching pharmacology and therapeutics will find this compilation of information extremely useful in preparing teaching materials"--Provided by publisher.
Author: Jacob V. Aranda Publisher: Lippincott Williams & Wilkins ISBN: 1975112490 Category : Medical Languages : en Pages : 2499
Book Description
The premier comprehensive textbook in the field, Yaffe and Aranda’s Neonatal and Pediatric Pharmacology, Fifth Edition, provides an authoritative overview of all aspects of drug therapy in newborns, children, and adolescents. It offers evidence-based guidelines for safe, effective, and rational drug therapy, including specific recommendations for all major drug classes and diseases. Now in a vibrant two-color format, this fully revised reference is an indispensable resource for pediatricians, neonatologists, pediatric residents, and fellows in different pediatric subspecialties, including neonatal medicine and pediatric critical care.
Author: Hannsjörg W. Seyberth Publisher: Springer Science & Business Media ISBN: 3642201954 Category : Medical Languages : en Pages : 385
Book Description
The objective of this volume is to give an overview of the present state of the art of pediatric clinical pharmacology including developmental physiology, pediatric-specific pathology, special tools and methods for development of drugs for children (assessment of efficacy, toxicity, long-term safety etc.) as well as regulatory and ethical knowledge and skills. In the future, structural and educational changes have to lead back to a closer cooperation and interaction of pediatrics with (clinical) pharmacology and pharmacy.
Author: Carole Kenner, PhD, RN, FAAN, FNAP, ANEF Publisher: Springer Publishing Company ISBN: 0826109764 Category : Medical Languages : en Pages : 1022
Book Description
"This book provides a complete look at neonatal healthcare delivery. This edition includes discussions of contemporary topics of interest, such as informatics, genetics, global health, and family-centered care, which are vital to providers caring for neonates today. The case studies and the evidence-based practice dialogues at the end of each chapter provide great opportunities for further reflection. The book is useful to a wide audience in nursing, including undergraduate and graduate nursing students, practicing neonatal and pediatric nurses, and advanced practice nurses who care for neonates." Score: 92, 4 Stars.--Doody's Medical Reviews This 'classic' has been thoroughly updated to incorporate the most up-to-date research findings and strategies for providing cost-effective and evidence-based care. New chapters address emerging infections, the late preterm infant, and neonatal care from a global perspective. Included are updated neonatal care protocols and procedures, neuroprotective risk factors, new treatments, and new trends in developmental care. Text integrates the Institute of Medicine's (10M) five competencies, reflects the Affordable Healthcare Act and the Robert Wood Johnson and 10M report "The Future of Nursing." The text continues to provide neonatal care from a physiologic and pathophysiologic approach, with a major emphasis on nursing management at the bedside and advanced practice level. Each neonatal body system is presented, along with E-B interventions to assist in understanding the 'why' behind what is seen in the clinical area. Integrative management is threaded through the text along with extensive research findings to support practice strategies and rationales for sound clinical decision-making. Topics of recent interest include iatrogenic complications, neonatal pain, use of computers or other technology in neonatal care, and neonatal AIDS. Case studies enhance understanding of both common and rare neonatal conditions. New to the Fifth Edition: New chapters: emerging infections, the late preterm infant, and neonatal care from a global perspective Updated neonatal care protocols and procedures, neuroprotective factors, new treatment modalities and new trends in developmental care Tackles the UN Millennium Development Goals (MDGs) Addresses the expansion of the nurse's role in the US and worldwide Provides case studies that lead the reader through the identification, diagnosis, treatment, and evaluation of common and rare neonatal conditions
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309225493 Category : Medical Languages : en Pages : 432
Book Description
The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Author: Stephanie J. Phelps Publisher: ISBN: 9781585283798 Category : Chemotherapy Languages : en Pages : 0
Book Description
For more than two decades, Pediatric Injectable Drugs (The Teddy Bear Book), has served an important and continuing need for reliable evidence-based information specific to pediatric injectable drugs. The tenth edition of this invaluable reference has grown to cover 238 drugs commonly used in the treatment of infants and children, including 20 new to this edition.
Author: Evelyne Jacqz-Aigrain Publisher: CRC Press ISBN: 0849374448 Category : Medical Languages : en Pages : 830
Book Description
The treatment of children with medicinal products is an important scientific area. It is recognized that many medicines that are used extensively in pediatric patients are either unlicensed or off-label. This textbook will help pediatric health professionals effectively treat children with the most appropriate medicine with minimal side effects.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309183642 Category : Medical Languages : en Pages : 135
Book Description
The Institute of Medicine's (IOM's) Roundtable on Research and Development of Drugs, Biologics, and Medical Devices evolved from the Forum on Drug Development, which was established in 1986. Sponsor representatives and IOM determined the importance of maintaining a neutral setting for discussions regarding long-term and politically sensitive issues justified the need to revise and enhance past efforts. The new Roundtable is intended to be a mechanism by which a broad group of experts from the public* and private sectors can be convened to conduct a dialogue and exchange information related to the development of drugs, biologics, and medical devices. Members have expertise in clinical medicine, pediatrics, clinical pharmacology, health policy, health insurance, industrial management, and product development; and they represent interests that address all facets of public policy issues. From time to time, the Roundtable requests that a workshop be conducted for the purpose of exploring a specific topic in detail and obtaining the views of additional experts. The first workshop for the Roundtable was held on April 14 and 15, 1998, and was entitled Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making. The summary on that workshop is available from IOM. This workshop summary covers the second workshop, which was held on May 24 and 25, 1999, and which was aimed at facilitating the development and proper use of drugs, biologics, and medical devices for infants and children. It explores the scientific underpinnings and clinical needs, as well as the regulatory, legal, and ethical issues, raised by this area of research and development.
Author: Sumner J. Yaffe
Author: Jacob V. Aranda
Author: Hannsjörg W. Seyberth
Author: Carole Kenner, PhD, RN, FAAN, FNAP, ANEF
Author: Institute of Medicine
Author: Sandra Benavides
Author: Stephanie J. Phelps
Author: Mark L. Glover
Author: Evelyne Jacqz-Aigrain
Author: Institute of Medicine